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Glioma regression requires the recruitment of potent anti-tumor immune cells into the 
tumor microenvironment. Dendritic cells (DCs) play a role in immune responses to these 
tumors. The fact that DC vaccines do not effectively combat high-grade gliomas, 
however, suggests that DCs need to be genetically modified especially to promote their 
migration to tumor relevant sites. Previously, we identified extracellular signal-regulated 
kinase (ERK1) as a regulator of DC immunogenicity and brain autoimmunity. In the 
present study, we made use of modern magnetic resonance methods to study the role of 
ERK1 in regulating DC migration and tumor progression in a model of high-grade 
glioma. We found that ERK1-deficient mice are more resistant to the development of 
gliomas, and tumor growth in these mice is accompanied by a higher infiltration of 
leukocytes. ERK1-deficient DCs exhibit an increase in migration that is associated with 
sustained Cdc42 activation and increased expression of actin-associated cytoskeleton-
organizing proteins. We also demonstrated that ERK1 deletion potentiates DC 
vaccination and provides a survival advantage in high-grade gliomas. Considering the 
therapeutic significance of these results, we propose ERK1-deleted DC vaccines as an 
additional means of eradicating resilient tumor cells and preventing tumor recurrence.  
 
  




High-grade gliomas, particularly glioblastoma multiforme (GBM), remain the least 
curable tumors with a high rate of recurrence and low survival rates (1). GBM evade 
elimination in many ways, particularly by promoting complex neovascularization 
networks (2) and prohibiting anti-tumor immunological surveillance (3). Therapeutic 
strategies will likely need to target these features from many possible angles to 
successfully eliminate tumors and prevent their recurrence. Feasible approaches include 
restoring, promoting and maintaining natural anti-tumor immune responses through 
immune cell therapies such as dendritic cell (DC) vaccines (4).  
DCs are potent antigen-presenting cells that have been shown to initiate adaptive immune 
responses. DC-based immunotherapies are being pursued as potential tools in curing 
GBM. DCs loaded with patient-derived tumor antigens have been investigated in early 
clinical trials that have yielded a therapeutic proof-of-principle (5). However, multiple 
phase III trials have not yet demonstrated a clear superiority of DC vaccination over 
standard chemotherapy, even though they have prolonged the median and overall survival 
rate of patients (4). Taking advantage of the full therapeutic potential of DC vaccines will 
require a better understanding of their role in eliminating tumor tissue. A major limiting 
factor in DC vaccinations is the small proportion of DCs (fewer than 5 %) that reach 
draining lymph nodes (LNs) following administration (6). This might hamper their 
therapeutic efficacy. Non-invasive methods such as MRI are therefore necessary to study 
DC migration as measure of therapy outcome and might help identify strategies 
overcoming the poor DC migration observed in patients (6). 
ERK MAP kinases have been shown to control cell migration by regulating cytoskeletal 
and focal contact dynamics (7). In myeloid DCs, persistent ERK activation leads to a 
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reduced migration of DCs, while ERK inhibition is associated with a higher migratory 
phenotype (8). Notably, ERK activation prevented immune cell infiltration in the 
articular capsule in autoimmune arthritis (9). Most studies have validated the role of 
ERK1 in combination with ERK2; it is however becoming clearer that these isoforms 
have explicitly different functions (10). When we specifically studied ERK1 in a model 
of neuroinflammation using bone marrow chimeras, we observed an increased infiltration 
of CD11c+ cells close to inflamed areas in the brain (11). ERK1 thus appears to be an 
important regulator of DC immunogenicity and its absence precipitates severe brain 
autoimmunity (11).  
Taking these findings into consideration, we hypothesized that ERK1 is an important 
regulator of DC migration and that its deletion might increase the migratory properties 
and vaccination efficacy of DCs towards high-grade gliomas. We used high resolution 
proton (1H) and fluorine (19F) MR methods to study the role of ERK1 in tumor 
progression as well as DC migration. ERK1-deficient mice were more resistant to the 
development of WT gliomas, and their tumors were highly infiltrated with Fascin+ and 
CD11c+ cells. We observed a marked increase in the in vitro and in vivo migration of 
Erk1-/- bone marrow derived DCs (BMDC). We also showed a marked reduction in tumor 
size and increase in survival following treatment of WT GBM mice with Erk1-/- DC, 
which suggests ERK1 deletion in DC vaccines as additional therapeutic strategy  against 
high-grade gliomas.    
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Materials and methods 
Preparation of retroviral vectors and transduction of murine cells 
The production of retroviral vectors MP71-OVA-IRES-GFP and the transduction of 
GL261 cells and murine T cells are presented in Supplementary Methods.  
Mice and glioma animal model  
All mice were handled according to the Berlin State review board at the Landesamt für 
Gesundheit und Soziales (LAGeSo) and internal (MDC) rules and regulations. The 
following mice were used: Erk1-/- mice on C57BL/6 background (12), their wild-type 
litermates, and Rag1-/-/OTI TCR transgenic mice recognizing the OVA-derived cognate 
peptide SIINFEKL on H2kb. Erk1+/+ × tdRFP and Erk1-/- × tdRFP  mice were generated 
by intercrossing Erk1-/- knockout mice (12) to ROSA26tdRFP reporter mice (13) and the F1 
generation. Following anesthesia and using stereotactic (David Kopf Instruments) 
coordinates referenced from bregma, glioma cells (2104 cells in 1-µl) were implanted in 
the striatum (anteroposterior 1mm; mediolateral ±1.5 mm; dorsoventral −4 mm).  
Dendritic cells 
Mouse dendritic cells were prepared from adult C57BL/6 mice as described (11). Briefly, 
BMDC were generated from femurs of WT or Erk1-/- mice. Cells were grown in RPMI 
1640 medium supplemented with 10% FCS and 30ng/mL GM-CSF (eBioscience). Cells 
were replenished with fresh GM-CSF medium every 3 days. On day 9, the fully 
differentiated BMDC were ready for further experiments.  
In vitro migration assays 
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Murine CD4+ T cells were sorted and activated with anti-CD3/anti-CD28 antibodies for 
72 h. For both murine BMDC and T cells, 600 µl of RPMI 1640 with or without 
recombinant stromal-derived factor CXCL12 (125 ng/ml, R&D Systems) was added to 
24-well plates (lower chamber). In some case, MEK inhibitor U0126 at 10 µM was 
applied 30 min prior to the assay. 100 µl of cell suspension (2105) was added to an 
upper chamber consisting of a transwell polycarbonate insert with 5-µm pore size (6.5 
mm diameter; Costar Corning). The cells were then allowed to migrate at 37 °C for 3 h. 
Cells in the lower chamber were then collected and counted by flow cytometry. 
Another method involved an agarose spot assay (14). Briefly, agarose spots with or 
without 2 µg/ml CCL19 (Peprotech) were placed onto 35-mm glass dishes (MatTek) and 
BMDC were added for 3 h. The migration of BMDC under the spots were determined by 
acquiring and fusing the microscope images for all the fields of views (FOV). Image 
processing and analysis were done with Fiji (Image J v1.47p).  
Flow cytometry  
TIL single cell suspensions (5105) were stained for 25 min at 4 °C with fluorescently 
conjugated antibodies in FACS buffer after blocking low affinity Fcγ receptor with 
CD16/CD32 antibody (BD Bioscience). The following antibodies were from Biolegend: 
APC-anti–mouse CD3 (clone: 145-2C11), PE-Cy7-anti–mouse CD11c (clone: N418), 
Pacific blue-anti–mouse CD8a (clone: RM4-5). For fascin1 (antibodies-online Inc.) 
staining, cells were fixed 10 mins with 4 % PFA then permeabilized 30 mins with 
methanol. Cytometry acquisition was on an LSRFortessa™ cell analyzer (BD) and 
analysis was done using FlowJo (Tree Star). 
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Cdc42 GTP loading and immunoblotting  
BMDC were treated with CXCL12 (100ng/ml) for 1 min and Cdc42 GTPase activity 
determined using a pull down and detection kit (Thermo Scientific). Total lysate (20µg 
protein) was incubated with a GST fusion protein, and then analyzed by 12% SDS-PAGE 
and immunoblotting according to the manufacturer’s instructions. Guanosine 5'-O-[γ-
thio] triphosphate (GTPγS) nucleotide was used as positive control. Membranes were 
incubated with secondary antibody and detected as previously described (15).  
MRI methods  
All in vivo MR measurements were performed on a 9.4 Tesla small animal MR system 
(Biospec 94/20, Bruker Biospin). Mice were anesthetized by inhalation narcosis using 0.5 
- 1.5% isoflurane (Baxter), pressurized air and oxygen. Core body temperature was 
maintained at 37°C. Respiration rate and temperature were monitored using a remote 
monitoring system (Model 1025, SA Instruments Inc.). For further details on MR 
methods, please refer to Supplementary Methods. 
Isolation and analysis of immune cells from glioma tissue   
Tumor infiltrating leukocytes (TILs) were isolated as described (16). TILs obtained from 
3 mice were pooled due to the limited cell number. Briefly, mice were transcardially 
perfused with PBS. Brain tumor tissue was extracted and mechanically dissociated using 
glass potter homogenizers (model TT57.1 Roth) into a crude suspension in RPMI 1640 
complete media followed by filtering with 40-µm cell strainer (BD Falcon). Cell 
suspensions were spun on Percoll gradient, centrifuged at 800g for 20 min, collected 
from the cell interface and washed 2 times with FACS buffer. For FACS analysis, please 
refer to Supplementary Methods. 




Mouse brains for sectioning were prepared as described (14). Sixteen µm thick brain 
sections were mounted on glass slides. After blocking, primary antibodies were added 
overnight at a dilution of 1:50 for CD11c or 1:25 for CD8a (BD Pharmingen) at 4°C. 
Alexa 488-conjugated goat anti-guanine pig IgG (Invitrogen) or Rhodamine Red™-X 
(Jackson ImmunoResearch) was subsequently applied. All images were taken using a 
confocal microscope (LSM 710, Zeiss) with a 20 objective.  
For detecting f-actin in BMDC, 1.5105 cells were plated on 1mg/ml poly-D-lysine 
(Sigma-Aldrich) coated glass cover slips. Cells were fixed with 4% PFA, and stained 
with rhodamine-coupled phalloidin (1:50; Molecular Probes®, Invitrogen). Images were 
taken by inverse fluorescence microscope (Leica) and digitized by Leica DC Viewer 3.2. 
For detecting fascin1 in BMDC, 2104 cells were plated on glass cover slips. Fixed cells 
were permeabilized with 0.01% Triton X100. The nuclei were counterstained with 
Hoechst 33342 (1:1000, Sigma-Aldrich). Images were taken using a confocal microscope 
(LSM 710 Zeiss) with a 40 objective.  
Quantification of CD8+ tumor infiltrating T cells  
Immunofluorescent staining sections from two animals of each group (PBS, WT-DC, and 
Erk1-/- DC treated) of glioma-bearing mice were used for quantification of CD8+ tumor 
infiltrating T cells. For each section, CD8+ T cells from at least 5 random fields within 
the tumor region were counted, each field measuring 1-2mm2. Cell number from each 
group were normalized with tumor area. Cell quantification was performed with Fiji 
(Image J v1.47p). 
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BMDC-T cell coculture and ELISA 
BMDC from WT and Erk1-/- mice (5104), preloaded with either SIINFEKL (1µg/ml, 
Biosynthan), full-length EndoGrade ovalbumin protein (1μg/ml; Hyglos) or OVA-GL261 
cell lysate (50µg protein/ml), were cocultured with 5104 OT1-TCR-transduced T cells 
(OT1-T cell).  PMA (20ng/ml) and ionomycin (1μg/ml) were used for positive controls. 
IFN-g concentration in was determined 24 h later by enzyme-linked immunosorbent 
assay (BD Bioscience).  
DC vaccination protocol 
BMDC from WT and Erk1-/- mice were incubated with GL261 cell lysate (50 µg protein 
/ml) and after 3 h, DCs were further matured with 0.5μg/ml LPS and incubate for 18 h. 
On day 3, 7, 10, and 14 following tumor implantation, WT mice were divided into 3 
groups and treated by intraperitoneal (i.p.) injections of either PBS or 2106 BMDC (WT 
BMDC, n=10; Erk1-/- BMDC, n=10; PBS, n=10). Survival studies were performed 
between different groups and the survival rate was calculated by the Kaplan-Meier 
method (MedCalc) using log-rank analysis.  
Statistical group analysis  
All data represent the average of at least triplicate samples. Error bars represent standard 
error of the mean (SEM). All data are presented as mean±SEM. Data were analyzed by 
Student's t test when compared between 2 groups. When comparing more than 2 groups, 
one way ANOVA was used in Microsoft Office Excel 2010. For multiple comparisons 
the Bonferroni correction was applied. Kaplan-Meier method was used for survival rate 
using log-rank analysis. The differences were considered statistically significant at 
*p<0.05, **p<0.01, and ***p<0.001.  




Glioma growth is diminished in ERK1-deficient mice  
The role of ERK1 in the glioma tumor microenvironment or its indirect impact on tumor 
progression is unknown. We stereotactically implanted WT GL261 glioma cells in the 
striatum of either WT or ERK1-deficient (Erk1-/-) mice. Using a previously established, 
high spatial resolution MRI protocol (14), we observed a marked reduction in glioma 
tumor growth in Erk1-/- compared to WT mouse brains 14 days post implantation (dpi) 
(Fig. 1A, left panel). Tumor volume was significantly smaller in Erk1-/- mice (9.6±1.1 
mm3) compared to WT mice (18.6±2.1 mm3) (Fig. 1A, right panel, p=0.00172). The 
survival rate in Erk1-/- glioma-bearing mice was also markedly improved compared to 
WT glioma mice (Fig. 1B, p=0.0002). Notably, two out of eleven Erk1-/- glioma-bearing 
mice exhibited complete tumor rejection. Altogether, these data indicate that the deletion 
of ERK1 in the stroma significantly attenuates glioma progression.  
Glioma-induced immune cell infiltration is regulated by ERK1 
High-grade gliomas contain brain-infiltrating peripheral immune cells among other cell 
types (17). We employed a 19F MR method (18) to study the way leukocytes leave the 
circulatory system and infiltrate the tumor site in WT and Erk1-/- mice harboring WT 
gliomas. Prior to 19F/1H MRI, rhodamine-19F nanoparticles (19) were i.v. injected into 
WT and Erk1-/- glioma-bearing mice (18 dpi) to label leukocytes traveling within the 
blood circulation (Fig. 2A). These cells take up nanoparticles, migrate into the brain, 
infiltrate glioma tissue (tumor-infiltrating leukocytes or TILs) and can then be visualized 
using 19F MRI. Upon segmentation of the whole tumor region, we calculated a 1.7-fold 
increase of total 19F signal within tumors in Erk1-/- mice compared to WT. Considering 
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the significantly smaller size of these tumors in the Erk1-/- mice, we next calculated the 
19F signal per tumor volume, which reflects the density of 19F-labeled TILs within the 
tumor and observed a 2.4-fold (p=0.0098) increase in Erk1-/- versus WT glioma-bearing 
mice (Fig. 2B, right panel). Ex vivo immunofluorescence staining also revealed that 
higher numbers of CD11c+/19F rhodamine-labeled cells infiltrated the tumor region in 
Erk1-/- brain sections compared to WT controls (Fig. 2C). Flow cytometry of TILs 
extracted from dissected whole tumor tissue revealed a significant increase in the 
frequency of CD11c+ cells in Erk1-/- mice (28.1 % in WT and 42.1 % in Erk1-/- mice, 
p=0.0473; Fig. 2D). More than 10 % of this CD11c+ population took up rhodamine-19F 
particles in vivo, representing cells that had infiltrated tumor tissue from the periphery. 
Notably, the number of CD11c+/19F rhodamine+ leukocytes was significantly higher in 
Erk1-/- mice (2.7±0.4 % from whole TIL fraction in WT and 4.9±0.4 % in Erk1-/- mice, 
p=0.0057; Fig. 2D). Of note, a large proportion of CD11c+ cells was rhodamine negative 
(Fig. 2D), one reason being that CD11c is also expressed on brain resident cells such as 
microglia; these are abundantly present around the glioma tissue and could still be 
present after preparation of the tumor tissue for FACS analysis. Other than CD11c+/19F 
rhodamine+ cells, the CD3+/CD8+ T cells from whole TIL fraction was also significantly 
higher in Erk1-/- mice compared to WT controls (3.1±0.6 % in WT and 10.7±2.2 % in 
Erk1-/- mice, p=0.0094; Fig. 2E), although the proportion of CD3+/CD8+ T cells that took 
up 19F rhodamine particles in vivo was very low (1-2 % of whole CD3+/CD8+ 
population). This can be explained by the low phagocytic properties of T cells.  
Overall, we demonstrate a significantly increased infiltration of CD11c+ immune cells 
and CD3+/CD8+ T cells from the periphery into glioma tissue in Erk1-/- mice. The 
recruitment of CD11c+ immune cells and cytotoxic T cells into glioma tissue is necessary 
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for an efficient anti-tumor response (20, 21). Therefore, an increased proportion of 
immune cells in tumor tissue of Erk1-/- mice (Fig. 2D and 2E) might explain the increased 
resilience of these mice towards developing gliomas (Fig. 1A) and their significantly 
increased rate of survival (Fig. 1B). 
ERK1 deficiency enhances dendritic cell migration 
The previous data (Fig. 2) show that a deficiency in ERK1 increases the accumulation of 
TILs. This is in line with previous findings that ERK activation after pharmacological 
inhibition of MEK-1 reduces DC migration towards the chemokines CCL21 (8), CCL19 
and CXCL12 (22). However, MEK-1 phosphorylates both ERK1 and ERK2, and these 
isoforms — despite their striking homology — have explicitly different roles. 
Considering the role of ERKs, in general, in controlling cell migration (7), we next 
investigated the role of ERK1 in DC and T cell migration through in vitro migration 
assays. CXCL12 is highly expressed in brain tumors and is a potent chemoattractant of 
CXCR4-expressing immune cells, including DCs and T cells (23). A modified Boyden 
chamber assay revealed that in comparison to WT T cells, Erk1-/- T cells exhibit a slight 
but not significant decrease in migration towards CXCL12 (Fig. 3A). MEK inhibition by 
UO126 (which inhibits both ERK1 and ERK2 activation) did not affect T cell migration 
in WT or Erk1-/- T cells. In contrast, Erk1-/- BMDC revealed significantly increased 
migration towards CXCL12 compared to WT BMDC (Fig. 3B). With the application of 
UO126, BMDC migrated to a slightly but not significantly lower extent towards 
CXCL12 (Fig. 3B). Migration inhibition following UO126 occurred at equal levels in 
WT and Erk1-/- BMDC.  
Targeting ERK1 in DC Vaccines for Glioma 
13 
 
The chemokine CCL19 plays a key role in the trafficking of DCs into LNs (24). To 
confirm the role of ERK1 in DC migration, we applied another in vitro assay. We 
observed a significant increase in the numbers (>3 folds, ***p<0.001) of Erk1-/- BMDC 
migrating towards CCL19-containing agarose spots 3 h after plating (Fig. 3C). 
Considering the increased migration of Erk1-/- BMDC towards CCL19, we then studied 
expression of CCR7 on these cells to determine possible mechanisms for the increased 
migratory properties. However, we did not observe an increase in CCR7 expression in 
immature and mature Erk1-/- BMDC when compared to WT BMDC (Fig. 3D). 
Given that migration is an important feature for DC homing to lymphoid organs (24), we 
next developed a noninvasive in vivo DC migration assay involving 19F/1H MRI and a 
labeling of BMDC with 19F nanoparticles in vitro prior to their application in vivo (25, 
26). In a WT mouse, one limb received 5×106 WT BMDC intradermally, and the other 
limb 5×106 Erk1-/- BMDC. Using this method we observed an increased migration of 19F-
labeled Erk1-/- BMDC (compared to WT BMDC) towards WT popliteal LN as shown by 
the 19F-signal in 19F/1H MRI (Fig. 4A). Ex vivo 19F MR spectroscopy of the extracted 
popliteal LNs (Fig. 4A) revealed at least twice as many 19F-labeled Erk1-/- BMDC 
(26.1×103 cells) reach the corresponding LNs compared to WT BMDC (11.8×103 cells) 
(p=0.028; Fig. 4B).  
We attributed the increase in the in vivo 19F signal following Erk1-/- BMDC application 
(Fig. 4A, 4B) and in Erk1-/- gliomas (Fig. 2B, 2C) to an increase in cell mobilization in 
tissue. However an increased 19F-signal could also be the result of an increased 19F 
nanoparticle uptake by Erk1-/- DC, inspite of our previous observations showing that 
Erk1-/- BMDC are more mature than WT BMDC (11). We then measured phagocytosis in 
BMDC following overnight incubation with 19F nanoparticles (same protocol as for the in 
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vivo experiments) by performing 19F MR spectroscopy. We did not observe any 
significant differences between WT and Erk1-/- BMDC to take up 19F nanoparticles (Fig. 
4C). We also did not observe any influence of the 19F nanoparticles themselves to 
significantly alter the phagocytic or migratory properties of both WT and Erk1-/- BMDC 
(data not shown).  
ERK1 controls cytoskeletal changes in DCs  
The Rho GTPase Cdc42 is a master regulator of DC polarity and is thus necessary for 
processes such as the reorientation of the microtubule-organizing center during 
endocytosis (27) and leading-edge coordination as decisive factors for DC motility in 
vivo (28). Interestingly, DCs have been shown to down-regulate Cdc42 activity following 
activation (27). To determine ERK1’s effects on Cdc42 regulation during DC migration, 
we performed Cdc42 activity assays in Erk1-/- and WT BMDC. Surprisingly, while 
Cdc42 activity was down-regulated in WT BMDC, this was not the case for Erk1-/- 
BMDC following stimulation with CXCL12 chemokine (Fig. 5A).  
Altogether our findings (Fig. 3, 5A, 5B) suggest that DC polarization is increased in the 
absence of ERK1. We thus measured filamentous actin (f-actin) in BMDC by FACS and 
found larger quantities of f-actin in Erk1-/- BMDC compared to WT BMDC (Fig. 5B).  
The large cytoskeletal protein talin is an adaptor protein associated with actin filaments 
and is required for actin polymerization. Immunofluorescence microscopy revealed an 
increase in cytoskeletal protrusions and a denser expression of f-actin and talin in Erk1-/- 
BMDC, particularly within the intracellular compartment (Fig. 5C). This indicates a 
higher level of cytoskeleton organization in Erk1-/- BMDC and might explain our 
observations of an increase in their motility and migratory potential in vitro (Fig. 3) and 
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in vivo (Fig. 4). Furthermore, the actin-bundling protein fascin1 is selectively expressed 
on DCs upon maturation (29) and is critical for the assembly of filopodia, thereby 
increasing cell motility (30). As shown in Fig. 5D (upper row), immature BMDC 
expressed lower levels of fascin1 in WT and Erk1-/- BMDC. Upon LPS-induced 
maturation, fascin1 expression was upregulated, an effect that was more pronounced in 
Erk1-/- compared to WT BMDC (Fig. 5D, lower row).  
Our data indicate that in contrast to WT BMDC, Erk1-/- BMDC maintain a high level of 
Cdc42 activity following activation and exhibit an abundantly polymerized cytoskeleton 
with fully assembled filopodia. This might aid the infiltration of DCs into tumor tissue 
(Fig. 2C and 2D). We also investigated the expression of fascin1 in CD11c+ cells that 
infiltrated glioma tissue. In glioma-bearing Erk1-/- mice, the number of fascin1-
expressing CD11c+ DCs in TILs isolated from dissected glioma tissue (18 dpi) was 
significantly higher than that from glioma tissue from WT mice (Fig. 5E, p=0.00334). 
These data provide further evidence of increased DC migration in the absence of ERK1, 
which could indicate a more potent anti-tumor response in ERK1-deficient DCs.  
ERK1 deficiency does not influence DC-T cell interaction 
A successful immune response to tumors depends on an effective crosstalk between DCs 
and T cells in priming tumor-specific CD8+ T cells (31). Since Cdc42-associated 
pathways are also necessary for microtubule-organizing center reorientation in DCs 
during antigen presentation to T cells (32), we investigated whether Erk1-/- BMDC mount 
a more potent anti-tumor T cell response. To explore this, we generated OVA-GL261 and 
transduced T cells with a T cell receptor (TCR) that specifically recognizes OVA-derived 
peptide in the context of MHC I (H-2Kb) (please refer to Supplementary Methods). To 
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test the specificity of the OVA-GL261 system, we stereotactically implanted OVA-
GL261 cells into the striatum of WT mice and OT1 mice (CD8 T cell TCR-transgenic 
recognizing OVA). Fourteen days following tumor cell inoculation, MRI revealed OVA-
GL261-induced glioma formation in the WT mice (Fig. 6A, left) but no sign of tumor 
formation in the OT1 mice (Fig. 6A, right). This confirmed the tumorigenicity of the 
OVA-GL261 glioma cells and efficient antigen recognition by OT1 T cells.  
We next investigated the capacity of Erk1-/- BMDC to cross-prime T cells. BMDC were 
isolated from WT and Erk1-/- mice and then pulsed with various antigens (LPS, OVA 
peptide, or OVA-GL261 lysate). Following co-culture with OT1-transduced T cells, we 
measured the secretion of IFN-gamma (IFNg) by ELISA. Secretion of IFNg has been 
proven to reflect both the extent of DC-mediated T cell cross-priming as well as cytotoxic 
properties of tumor antigen-specific CD8+ T cells (33). We did not observe any 
differences between the capacity of WT and Erk1-/- BMDC to prime IFNg secretion in 
tumor-specific T cells (Fig. 6B).  
ERK1 deficiency enhances antitumor activity of DC vaccines against high-grade 
glioma  
Brain tumor regression requires the recruitment of functional DCs into the glioma 
microenvironment (20). Since we observed a higher migratory potential of Erk1-/- BMDC 
in vivo, we next asked whether ERK1 deficiency might have a beneficial impact on DC 
vaccination in GBM. To examine the therapeutic efficacy of Erk1-/- BMDC, we 
vaccinated glioma-bearing mice twice a week with WT or Erk1-/- BMDC, which were 
pulsed with GL261 lysate, and performed 1H MRI 18 dpi (Fig. 7A). The size of tumors in 
glioma-bearing mice that received WT BMDC was slightly smaller than PBS treated 
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glioma-bearing mice (20±5 mm3 and 30.9±2.8 mm3, respectively; p=0.0803). On the 
other hand, tumor size in glioma-bearing mice that received Erk1-/- BMDC vaccines 
(8.4±2.9 mm3; p=0.000035 when compared to PBS group) was significantly smaller than 
in untreated glioma-bearing mice (Fig. 7B, right panel). Notably, WT BMDC did not 
show a significant effect on tumor size reduction at this time point (18 dpi). Consistent 
with previous observations made in glioma-bearing mice (34), mice receiving WT 
BMDC pulsed with GL261 lysate still exhibited significantly enhanced survival when 
compared to untreated PBS controls (Fig. 7C). When compared with the untreated PBS 
group, WT BMDC had a higher survival probability (p=0.0019). Furthermore, in line 
with a markedly decreased tumor size, we documented significantly improved survival 
probability in glioma-bearing mice receiving Erk1-/- BMDC compared to those of 
untreated mice (p=0.0005) (Fig. 7C). 
We next wanted to study the distribution of both Erk1-/- and WT BMDC in the glioma 
model following intraperitoneal application (Fig. 7D). For this we employed BMDC that 
were derived from either (Erk1-/- × tdRFP) mice or (Erk1+/+(WT)× tdRFP) littermate 
control mice. Although we could not detect any of the injected RFP BMDC (both WT 
and Erk1-/-) in the brain of glioma mice 21 dpi, we observed a significant increase in 
CD11c+ RFP+ BMDC in the lymph nodes of mice treated with (Erk1-/- × tdRFP) BMDC 
when compared to mice treated with (Erk1+/+(WT)× tdRFP) BMDC (Fig. 7D). These 
results in the glioma model are in line with our in vitro assays (Fig. 3) and in vivo 
experiments in WT healthy mice (Fig. 4A).  
Although we could not detect any of the intraperitoneally-administered (WT or Erk1-/-) 
BMDC  in the brain of glioma-bearing mice, we observed differences in the expression of 
tumor-infiltrating CD8+ T cells between the different treatment groups (Fig. 7E). While 
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tumor sections demonstrated visibly smaller tumors when treated with BMDC, the 
number of CD8+ T cells was significantly increased in sections derived from mice treated 
with WT BMDC compared to PBS-treated groups (1359±39 cells/mm2 and 716±24 
cells/mm2, respectively; p=0.001). The infiltration of CD8+ cells was further enhanced 
when treating mice with Erk1-/- BMDC (1920±49 cells/mm2; p=0.02 when compared to 





















In this report, we identify ERK1 as a regulator of DC migration and show that the 
introduction of DCs lacking ERK1 lead to a significant reduction in tumor growth as well 
as improved survival of glioma-bearing mice.  
DCs need to actively migrate between lymphatic tissue and interstitial spaces to initiate 
adaptive immune responses. Here we demonstrate that ERK1 plays a crucial role in the 
migratory capacity of DCs. This key ERK-MAPK intracellular signaling pathway 
transduces a broad range of extracellular stimuli into important biological responses 
including cell survival, proliferation, differentiation, and the regulation of DCs (9, 35) 
and T cells (36). The specific role of ERK1 has been studied in T cells and it was shown 
that ERK1 does not appear to play a direct role on the effector function of antigen-
specific T cells, notwithstanding increased susceptibility towards T cell mediated 
autoimmunity (37). In DCs, ERK1 inhibits cytokine production following their 
stimulation by TLRs (38) and reduces surface receptors (11), which in turn affects the 
priming of naïve T cells towards an effector phenotype during autoimmunity (11). Most 
studies of tumor pathology have not distinguished ERK1 from ERK2 function, due to the 
assumption that they have compensatory effects (39). However, in some biological 
contexts the distinction between these two kinases appears to be crucial, considering that 
ERK2-deficient mice are embryonically lethal (40) in contrast to ERK1-deficient mice, 
which are viable and fertile (12). Here we report for the first time a role for ERK1 in 
negatively regulating the migration specifically of DCs by showing a significant increase 
in migration in Erk1-/- BMDC, both in in vitro and in vivo experiments. In vitro, we 
distinguished between the impact of ERK1 on BMDC and effector T cells. Although 
ERK1 is expressed in both cell types, its role in migration was more pronounced in DC 
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than in T cells. Furthermore, while ERK1 deletion promoted DC migration, application 
of a MEK inhibitor (U0126) inhibited DC migration. Since U0126 inhibits both ERK1 
and ERK2 activation, this might have masked the increase in migration we observe in the 
absence of ERK1 and could furthermore explain discrepancies in earlier studies using 
inhibitors to ascertain the signals’ roles in migration-related processes (41).  
Migratory phenotypes typically involve mechanisms related to cytoskeletal organization 
and structure, so we studied this aspect of ERK1’s influence. We showed that ERK1 
influences the cytoskeleton and associated adaptor and actin-bundling proteins such as 
talin and fascin1, another strong piece of evidence for a role of ERK1 in the regulation of 
DC migration. We chose fascin1 as a marker for dendritic cells in the tumor tissue, since 
CD11c+ is not an exclusive marker for these cells in brain gliomas: CNS resident and 
non-resident immune cells such as peripheral macrophages (42) are also CD11c+. 
Importantly, fascin1 is not expressed on activated microglia (43) and peripheral blood 
cells, including macrophages and neutrophils (44).  
A role for ERK1 in DC migration is additionally supported by our finding that ERK1 
deletion promotes Cdc42 activation, since Cdc42 is responsible for leading edge 
coordination in vivo (28). Notwithstanding the role of Cdc42 in DC polarity and 
orientation during antigen presentation to T cells (32), Erk1-/- DCs did not present OVA-
GL261 (as model-tumor antigen) to T cells more effectively than WT DCs. This excludes 
tumor antigen presentation as an underlying mechanism for the decreased susceptibility 
of Erk1-/- mice to develop gliomas and for the increased infiltration of T cells in WT 
gliomas in these mice compared to WT mice. The observation indicates that the benefits 
of ERK1 deficiency in reducing the growth of gliomas likely derive from an ultimate 
increase in immune cell surveillance in the glioma tissue as shown by an increase in 
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CD11c+ leukocytes, fascin1+ DCs and CD8+ T cells in Erk1-/- glioma-bearing mice as well 
as increase in CD8+ T cells in Erk1-/- BMDC-treated glioma-bearing mice. From our 
results, we believe that ERK1 deficiency is better adapted for providing a higher 
availability/localization of BMDC in the periphery rather than increasing tumor antigen 
presentation and therefore priming of antigen-specific cytotoxic T cells. Although we did 
not detect the administered Erk1-/- BMDC in the tumor tissue following therapeutic 
application in the glioma model, we did observe a significantly increased proportion of 
Erk1-/- RFP+ cells in the LNs and an increased CD8+ population of T cells infiltrating the 
tumor tissue.  
Ultimately, improved immune cell surveillance would also augment the reactivation and 
expansion of cytotoxic T cells within tumor-relevant sites. Our results suggest that the 
enhanced therapeutic properties of Erk1-/- BMDC could be the result of an improvement 
in the delivery of Erk1-/- BMDC to the lymphatic tissue which eventually results in a 
larger infiltration of CD8+ T cells into the tumor tissue. A recent NIH-funded clinical trial 
found that improving the LN homing of DCs in GBM patients significantly enhances the 
therapeutic efficacy of tumor antigen–loaded DCs (45). Their finding and our study 
suggest that monitoring DC migration might deliver a predictive readout for the 
effectiveness of DC vaccines.  
Here we used 19F MR to do this, and although still in early clinical development (46), it 
might offer significant advantages in the future over other methods to track DC migration 
such as scintigraphy combined with radioisotope 111In-oxine (47). MRI in general was 
shown to be better at localizing DC vaccines in vivo (48); paramagnetic iron oxide 
nanoparticles were used to label and follow cells in melanoma patients (48). Even though 
this represented a major step forward in the tracking of DCs, lower image contrast often 
Targeting ERK1 in DC Vaccines for Glioma 
22 
 
makes it difficult to distinguish MRI signal hypointensities originating from 
magnetically-labeled cells from hypointensities caused by endogenous factors (e.g. 
deoxygenated blood). 19F MR-based methods were simultaneously introduced in animal 
models to overcome these hurdles in cellular MR imaging (49).  
The elegance of 19F MR lies in the fact that it provides background-free images in 
mammals and permits a highly selective detection of cells in vivo throughout the 
organism’s body (50). The main hurdle is signal sensitivity, which can pose a challenge 
when imaging 19F-labeled DCs in cancer patients (46). In a recent report we aimed to 
promote the signal achieved per unit cell; we enriched 19F nanoparticles with the 
phosphatidylethanolamine DPPE and observed a stronger enhancement of 19F signal 
(from 74 nmol to 771 nmol) per 106 cells, which equates to an order of magnitude  
increase in 19F spins from 0.89 × 1012 19F spins (control nanoparticles) to 0.93 × 1013 19F 
spins (in DPPE-enriched nanoparticles) per DC unit (19). In the present study we made 
use of the recently developed 19F marker (19) to label and track DCs in vivo with greater 
sensitivity and to determine the role of ERK1 in DC migration.  
We can follow the 19F signal from DCs that we had administered and showed that Erk1-/- 
DCs migrate more readily than WT DCs into popliteal LNs. We also quantified the 19F 
signal and thereby the number of DCs in draining LNs by ex vivo 19F MRS and observed 
a significant increase in the number of Erk1-/- DCs compared to WT DCs that appeared in 
the corresponding draining LNs. While further developments in 19F MR will be needed to 
expand its use in clinical applications (51), it is a valuable tool to monitor DC homing in 
cancer therapy and to effectively interpret the in vivo distribution of DCs as a means of 
assessing the effectiveness of these therapies in GBM patients. The advent of 
cryogenically cooled MR detectors (52) will help boost 19F MR sensitivity and lower 
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detection levels of 19F-labeled cells to facilitate in vivo cell tracking within shorter scan 
times. 
Here we identified ERK1 as a molecular player that negatively regulates the mobility of 
DCs and their capacity to eliminate malignant gliomas. The results were demonstrated in 
a preclinical mouse GBM model and further studies will be required to predict the safety, 
efficacy and potential benefits of Erk1-/- DC vaccines in human high-grade or recurrent 
gliomas. While the present study is restricted to the role of ERK1 against GBM, effective 
therapies will likely need to target the tumor from many different angles, employing 
several approaches toward tumor cell elimination while preserving sufficient natural anti-
tumor immune responses. Other strategies such as the preconditioning of application sites 
with recall antigen to promote DC vaccination in humans and mice (45), as recently 
reported further emphasizes the need to promote DC migration as a means of optimizing 
DC vaccines. As negative regulator of DC migration, ERK1 appears to be an attractive 
target for deletion in genetically modified vaccines. Other possible molecular targets 
include molecules such as IRF4 (53) and CD37 (54), which favor DC migration. It has 
now become practical to apply simultaneous gene silencing and retroviral transgenic 
insertion; such combinations have proven to be highly effective (55, 56).  Ex vivo gene 
silencing in immune cell therapeutics using both viral and non-viral based approaches has 
been an area of intensive research in clinical trials  during the last decade (57) 
In summary, our study demonstrates the advantage of specific gene manipulation in DC 
vaccines to promote their migration and efficacy in reducing tumor progression in an 
animal model of GBM. Furthermore, this study underscores the benefits and needs of 
using 19F MRI to measure in vivo cell migration and localization, which are critical 
parameters in the effectiveness of such vaccines. ERK1 and other molecular targets that 
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enhance DC migration will be important tools in developing a next generation of DC 
vaccines (45). The overall survival of GBM patients could well be improved by patient-
specific treatment regimens that use immunotherapy based on genetically modified cells 
in conjunction with standard treatment protocols (surgery, radiotherapy, chemotherapy, 
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Figure 1 Erk1-/- mice have a restricted glioma growth. (A) Left panel: MRI images of 
glioma bearing WT and Erk1-/- mice were acquired 14 days following intracranial 
implantation of 2104 GL261 cells using a 9.4 T animal MR system. Glioma tissue was 
segmented: white dashed line surrounds tumor area. Right panel: Following 
segmentation, a volumetric assessment of the glioma tissue was made in WT (n=11) 
versus Erk1-/- mice brains (n=11). Error bars represent mean ± SEM; **, p<0.01. (B) 
Kaplan-Meier survival rate curves for both WT (n=11) and Erk1-/- (n=11) glioma-bearing 
mice. Statistical significance was determined by log-rank testing, ***, p<0.001. 
 
Figure 2 Erk1-/- mice harbor more glioma-infiltrated leukocytes. (A) 18 dpi, 
rhodamine-19F nanoparticles were injected into WT and Erk1-/- glioma-bearing mice via 
tail vein 18 h prior to 19F/1H MRI. After 19F/1H MRI, WT and Erk1-/- glioma-bearing 
mice were perfused to remove excess rhodamine-19F nanoparticles and processed for ex 
vivo FACS or histology analysis. (B) Left panel: Representative 19F/1H MRI of glioma-
bearing WT and Erk1-/- mouse brains. Mouse brain anatomy (1H grayscale image) is 
shown overlaid with immune cells labeled with rhodamine-19F nanoparticles in vivo (19F 
red pseudocolor image). Yellow dashed-line surrounds tumor area. Right panel: Intensity 
of 19F signal from WT (n=8) and Erk1-/- (n=8) glioma-bearing mice was normalized to 
tumor volume (19F intensity/mm3). Error bars represent mean ± SEM; **, p<0.01. (C) 
Representative immunofluorescent staining of CD11c (green) and rhodamine (red) signal 
in brain tumor sections of WT or Erk1-/- mice, which were injected with rhodamine-19F 
nanoparticles. Bars: 50 µm. (D) 18 dpi, TILs were isolated from WT and Erk1-/- glioma-
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bearing mice and analyzed by FACS. Representative dot plots of glioma-infiltrating 
CD11c+ DCs and CD11c+ DCs which also took up rhodamine-19F nanoparticles. 
Percentage represents the cells from gating of living cells. (E) Representative dot plots of 
CD3+/CD8+ T cells from infiltrating TILs. All FACS data are representative of 5 
independent experiments with pooled 3 mice per group. Values represent mean ± SEM; 
**, p<0.01.   
 
Figure 3 ERK1 deficiency leads to increased DC migration in vitro. (A) WT or Erk1-/- 
T cell migration towards CXCL12 was tested using a modified Boyden chamber. (B) WT 
or Erk1-/- BMDC migration was also measured using the same method. Bars represent 
mean ± SEM; *, p<0.05; **, p<0.01. (C) Histogram overlay of CCR7 expression in WT 
or Erk1-/- BMDC as measured by flow cytometry prior to and after maturation with  LPS. 
(D) Representative light microscopic images of WT or Erk1-/- BMDC (1×106 per plate) 
migrating towards CCL19. White dashed-lines represent the edge of agarose spot. White 
arrows depict the migration direction.  Right panel shows quantified data from at least 3 
independent experiments and at least 2 agarose spots per group. Error bars represent 
mean ± SEM; ***, p<0.001.  
 
Figure 4 ERK1 deficiency leads to increased DC migration in vivo. (A) WT and Erk1-
/- BMDC labeled with 19F nanoparticles were injected in the left (WT BMDC) and right 
(Erk1-/- BMDC) footpad of WT mouse (n=13) and their migration towards the popliteal 
LNs imaged by 19F/1H MRI after 4 h.  Mouse lower limb anatomy (1H grayscale image) 
is shown overlaid with BMDC labeled with 19F nanoparticles (19F red pseudocolor 
image). (B) After 19F/1H MRI, both popliteal LNs were harvested and the number of 19F-
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labeled BMDC quantified by 19F MR spectroscopy (MRS) of LNs and BMDC calibration 
samples. 19F MR spectroscopy demonstrated significantly more 19F-labeled DCs 
migrating in LNs for Erk1-/- BMDC versus WT BMDC.  Error bars represent mean ± 
SEM; *, p<0.05. (C) The phagocytic properties of WT and Erk1-/- BMDC towards 19F 
nanoparticles were compared by measuring the 19F signal using 19F MR spectroscopy for 
both groups in a calibration curve ranging from 5104  to 5106 BMDC.  
 
Figure 5 Erk1-/- BMDC display a more polarized cytoskeleton. (A) Activity of Cdc42 
GTPase of WT and Erk1-/- BMDC that were untreated or pretreated with CXCL12 was 
determined by pull-down assay and consecutive Western blot analysis (n=4). (B) 
Expression of intracellular f-actin on WT (solid line) or Erk1-/- (filled black histogram) 
BMDC as assessed by FACS. Dashed line histograms depict control staining with anti-
mouse IgG. Data represent 4 independent experiments. (C) Immunofluorescence staining 
of talin (green, left column), f-actin (red, middle) and Hoechst 33342 nuclei (blue, right) 
on WT and Erk1-/- BMDC attached to glass coverslips. Bar, 10 µm. (D) 
Immunofluorescence staining of fascin1 (red) on WT and Erk1-/- BMDC without (upper 
row) and with LPS stimulation (lower row). Data represent 3 independent experiments. 
Bar, 25 µm. (E) Representative dot plots of glioma-infiltrating fascin1-expressing 
CD11c+ DC as determined by FACS. TILs were isolated from WT and Erk1-/- glioma-
bearing mice on 18 dpi. Data represent 5 independent experiments. Values represent 
mean ± SEM; **, p<0.01. 
 
Figure 6 Antigen-specific T cell activation in Erk1-/- BMDC remains unaltered. (A) 
MRI images show OVA-specificity: OVA-GL261 cells were inoculated in WT (n=3) or 
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OT1 transgenic mice (n=6) and tumor growth was monitored by 1H MRI on 14 dpi. 
Yellow dashed-line surrounds tumor area in WT mouse. WT-GL261 transplanted in both 
WT mice (n=3) and OT1 transgenic mice (n=3) served as control (right panel). (B) WT 
and Erk1-/- BMDC were treated with OVASIINFEKL peptide or OVA-GL261 cell lysate and 
then co-cultured with OT1-transduced T cells. OT1-T cells and non-transduced (WT) T 
cells were also cultured with PMA plus Ionomycin as positive control for IFNg 
production (right panel). Serving as negative controls (but are not shown) were non-
transduced WT T cells activated by WT and Erk1-/- BMDC loaded with OVASIINFEKL 
peptide or OVA-GL261 cell lysate, as well as untreated BMDC and LPS-treated BMDC. 
IFNg production was measured by ELISA. Data are representative of 3 independent 
experiments. Bars represent mean ± SEM. 
 
Figure 7 Erk1-/- BMDC improve immunotherapy against high-grade glioma. (A) 
Schematic representation of DC vaccination protocol in glioma-bearing mice. (B) WT 
and Erk1-/- BMDC (2×106) loaded with 50 µg GL261 cell lysate and activated with LPS 
were administered to glioma-bearing WT mice via i.p. injection 3, 7, 10, and 14 dpi. 
Mice receiving PBS i.p. injections served as negative control. Tumor growth was 
validated 18 dpi by MRI. Data are representative of 3 independent experiments with at 
least 3 animals per group. Bars represent mean ± SEM; ***, p<0.001. (C) Kaplan-Meier 
survival curves were plotted for PBS (n=10), WT BMDC (n=10) and Erk1-/- BMDC 
(n=9) treated glioma animal groups. Statistical significance was determined by log-rank 
testing (**, p<0.01, WT BMDC vs PBS; ***, p<0.001, Erk1-/- BMDC vs PBS). (D) At 21 
dpi, lymphocytes were isolated from glioma-bearing mice and analyzed for RFP+ cells by 
FACS. All FACS data are from 2 independent experiments with 3 mice per group. Values 
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represent mean ± SEM; *, p<0.05. (E) Representative immunofluorescent staining of 
CD8a (red) and DAPI (blue) signal in brain tumor sections of WT mice, which were 
receiving either PBS, WT BMDC or Erk1-/- BMDC. Bar: 50 µm. Yellow dashed-lines 
represent the edge of tumor. Right panel shows quantified cell number from 2 
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Retroviral vectors and virus supernatant 
Full-length OVA-sequence was amplified from pLOVASN via PCR using following primer-
sequences: 5´-ATAGTCGACCACCATGGGCTCCATCGGTG-3 (fwd) and 5´-
ATAGCGGCCGCTTAAGGGGAAACACATCT-3 (rev). Underlined are the introduced 
restriction-sites for SalI and NotI. After digestion of the pMP71-IRES-GFP vector and the 
resulting amplicon with SalI and NotI restriction enzymes, both DNA-fragments were ligated 
using a Rapid DNA Ligation Kit (Roche). The resulting construct, pMP71-OVA-IRES-GFP, was 
verified by digestion with PstI restriction enzyme as well as DNA sequence analysis. Ecotropic 
viral vectors were produced using the Platinum-E packaging cell line (1). Viral supernatants were 
harvested 48 h following transfection, filtrated (0.45-μm pore size) and stored at -80 °C. 
Transduction of GL261 cells and murine T cells 
GL261 murine glioma cells (National Cancer Institute) were cultured at 37 °C and 5 % CO2 in 
RPMI 1640 with 200 mM glutamine, 50 U/ml penicillin, 50 µg/ml streptomycin, and 10 %  FBS 
(all from Invitrogen). GL261 cells (5  104) were seeded into 24-well plates and after 16 h, 1 ml 
viral supernatant supplemented with 4 μg/ml protamine sulfate (Sigma-Aldrich) was added prior 
to centrifugation for 1.5 h (800 g, 32 °C). After 24 h, the supernatant was exchanged with viral 
supernatant (2 ml) supplemented with protamine sulfate and 48 h later, the cells were analyzed by 
flow cytometry for expression of GFP and H2kb-SIINFEKL complexes. Transduction efficiency 
reached 76% for MP71-OVA-IRES-GFP. To generate a 100 % GFP+H2kb-OVA+ cell 
population, these cells were bulk-sorted using a FACSARIA II (BD Biosciences). 
To transduce murine primary splenocytes,  2  106 cells/ml were supplemented with 1 µg/ml anti-
CD3 mAb, 0.1 µg/ml anti-CD28 mAb (BD Biosciences) and 10 IU IL-2 (Proleukin Novartis) and 
cultured overnight. The cell density 1  106 per ml were seeded in 24 well plates coated with 12.5 
µg/ml RetroNectin (Takara) and supplemented with 4  105 beads/ml mouse T-Activator 
CD3/CD28 (Life Technologies), 10 IU/ml IL-2, 4 μg/ml protamine sulfate and virus-containing 
supernatant (MOI = 2). Following centrifugation for 1.5 h (800 g, 32 °C), the cells were 
incubated at 37 °C for 48 h. The medium was replenished with 10 ng/ml human recombinant IL-
15 (Peprotech). 
MRI methods  
For in vivo MR measurements, mice were anesthetized shortly before and during the MR session 
using a mixture of isoflurane (Baxter) as inhalation narcosis (0.5 - 1.5%), pressurized air and 
oxygen. The core body temperature of the mice was maintained at 37 °C. Respiration rate and 
temperature were monitored using a remote monitoring system (Model 1025, SA Instruments 
Inc.).  
In vivo assessment of glioma growth using 1H MR microscopy. For comparing glioma tumor size 
in WT and Erk1-/- glioma-bearing mice, mice brain were imaged on day 14 after the 
intracereberal inoculation of GL261 cells (14 dpi). For comparing glioma tumor size after 
vaccination, mice were imaged 18 dpi after the intracereberal inoculation of GL261 cells. 
Anesthetized mice were placed below a cryogenically-cooled quadrature radiofrequency (RF) 
coil (CryoProbe, Bruker Biospin) tailored for mice brain MR (2). T2-weighted images (RARE, 
repetition time (TR) = 3268 ms, echo time (TE) = 60 ms, RARE factor = 12, 8 averages) were 
acquired with the same slice geometry (FOV = (1818) mm2, matrix size = 350350, slice 
thickness = 270 µm, in-plane spatial resolution = 51 µm, 21 coronal slices covering a brain 
region of 5.67 mm starting at the frontal end of the cerebral cortex (approx. Bregma 3.56 to -2.11 
mm) (3). Tumor regions were manually segmented and the volume calculated in Fiji by adding 
up the voxel volumes. 
Imaging inflammatory cell infiltration using in vivo 1H/19F MRI. For studying infiltration of 
immune cells from the peripheral circulation into glioma tissue, glioma-bearing mice were 
injected with rhodamine-tagged 19F nanoparticles containing 80 µmol perfluoro-15-crown-5-ether 
(PFCE) 18 dpi via tail vein. After 18 h of injection, 1H/19F MRI was performed using an in-house 
built dual-tunable 19F/1H head coil (4) and a protocol consisting of a 3D RARE sequence with an 
isotropic resolution of 250 µm³ for 19F  (TR/TE = 800/5.9 ms, 128 averages) and of 125 µm³ for 
1H (TR/TE = 1500/47 ms) MRI. 19F signal intensity was calculated in Fiji. 
Visualizing in vivo BMDC migration using 1H/19F MRI. BMDC were incubated with 19F 
nanoparticles (containing 20 µmol PFCE) and 1 μg/ml full-length chicken EndoGrade ovalbumin 
(endotoxin conc.<1 EU/mg; Hyglos). BMDC were further matured by 0.5 μg/ml 
lipopolysaccharide (LPS). Following overnight incubation, unbound 19F nanoparticles were 
washed thoroughly from the culture with warm PBS. BMDC were then harvested and applied 
intradermally into hind limbs (one limb received 5×106 WT BMDC, the other received 5×106 
Erk1-/- BMDC) of WT mice and imaged 4 h after injection. Using a 1H/19F dual-tunable volume 
birdcage resonator (Rapid Biomed), gradient echo images were acquired using a 3D-FLASH 
sequence for 19F (TR/TE = 8/3 ms; 80 averages, flip angle = 10°) and for 1H (TR/TE = 11/4 ms; 8 
averages, flip angle = 15°).  
In vitro 19F MR Spectroscopy (MRS). Following harvesting, BMDC (1×106) labeled with 19F 
nanoparticles were fixed in 2 % paraformaldehyde (PFA) and transferred to NMR tubes (external 
diameter: 4.947 ± 0.019 mm; Wall thickness: 0.043 ± 0.02 mm; VWR International GmbH) and 
the uptake of 19F nanoparticles monitored by 19F spectroscopy. Different BMDC numbers were 
employed to achieve a 19F signal to cell calibration. We employed an in-house built 19F-tuned 
loop RF coil (5) for signal transmission and reception and a 90° block pulse with 10 kHz 
bandwidth for 19F signal excitation. The amount of PFCE in each sample was calculated from the 
amplitude of the extrapolated monoexponential decay, at t=0 of the free induction decay (FID) 
19F MR signal, which is proportional to the 19F concentration. A standard consisting of 500 mM 
PFCE was used as quantitative reference in all of these experiments. The same MRS method was 
employed to measure the 19F signal in popliteal LNs extracted from mice following intradermal 
application of 19F-labeled BMDC. The number of 19F-labeled BMDC in each LN was quantified 
using the BMDC calibration curves. NMR data processing and analysis were performed in 
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